title: Local delivery of antithrombin inhibits platelet deposition after balloon injury in a porcine coronary model.
abstract: BACKGROUND
  Thrombin activation and initiation of the coagulation process can lead to thrombotic complications after coronary angioplasty. A therapeutic approach may be effectively to inhibit thrombin activity at the site of the vessel wall injury.
  
  
  OBJECTIVE
  The aim of the present study was to investigate the short-term effects of local delivery of antithrombin on coronary vessel wall injury in pigs.
  
  
  METHODS
  A coronary balloon angioplasty was performed in the left anterior descending artery. Twenty-four hours before the procedure, platelets were marked with Indium 111 and infused into the pig. Before catheterisation 100 U/kg of heparin was administered. Eight pigs received 250 U (5 ml) of antithrombin and, as a control, eight received 10 mg of albumin (5 ml) delivered using a local drug delivery balloon catheter. Microscopic preparation of the injured part of the vessel was performed, and the amount of radioactivity was measured, giving the number of platelets per cm2. Plasma antithrombin level was measured before and after local delivery. The amount of antithrombin in the vessel wall was measured using a semi-quantitative method involving anti-antithrombin antibodies.
  
  
  RESULTS
  The number of platelets per cm2 was significantly lower in the antithrombin group (mean 2.3 x 10(6)) than in the control group (6.3 x 10(6), P= 0.02 ). No macroscopic thrombus was detected in the antithrombin group, whereas three out of eight pigs in the control group had visible thrombus formation (NS). There was an increase in the plasma concentration of antithrombin after local delivery. In the antithrombin group, antithrombin was detected in the intima, the lumen part of the media and in the vasa vasorum.
  
  
  CONCLUSIONS
  Antithrombin can be administered and deposited locally in the coronary vessel wall thereby reducing platelet deposition after balloon injury.
authors.affiliation: Division of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: F
authors.initials: F
authors.lastname: Scherstén
authors.forename: T
authors.initials: T
authors.lastname: Björnheden
authors.forename: H
authors.initials: H
authors.lastname: Emanuelsson
authors.forename: O
authors.initials: O
authors.lastname: Wiklund
authors.forename: L
authors.initials: L
authors.lastname: Grip
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D000991:Antithrombins / Q000008:administration & dosage* / Q000627:therapeutic use; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D016503:Drug Delivery Systems / Q000295:instrumentation; D010974:Platelet Aggregation; D013552:Swine; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D000991:Antithrombins